CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2021—Roche has launched the Avenio Tumor Tissue Comprehensive Genomic Profiling Kit, complementing the current CGP portfolio offered by Roche and Foundation Medicine.
The Avenio Tumor Tissue CGP Kit is a research use only, next-generation-sequencing test that provides an end-to-end workflow from DNA extraction and library preparation to generation of variant results by the FoundationOne analysis platform via Avenio Connect. The kit uses a gene panel based on the FoundationOne platform that was designed to match the FoundationOne CDx panel content to analyze 324 cancer-related genes across four main classes of genomic alterations and genomic signatures known to cause and drive cancer.
Each of the kits is configured for running 24 samples and runs on Illumina’s NextSeq 500/550 RUO and NextSeq 550 Dx system in research mode. Results are available in five days.